See the DrugPatentWatch profile for vevye
Does Vevye Reduce Inflammation in Dry Eye Syndrome?
Vevye (cyclosporine ophthalmic solution 0.1%) is FDA-approved for treating signs and symptoms of dry eye disease, including inflammation. It works as a calcineurin inhibitor to reduce ocular surface inflammation by suppressing T-cell activation, a key driver in dry eye syndrome.[1][2]
Clinical trials showed Vevye significantly improved corneal staining (a marker of epithelial damage from inflammation) and tear production compared to vehicle in patients with moderate to severe dry eye. In two 12-week phase 3 studies (STRIDE 1 and 2), 54-58% of Vevye users achieved ≥1-grade improvement in corneal staining versus 37-41% on vehicle.[3]
How Does Vevye Target Dry Eye Inflammation?
Dry eye syndrome often involves chronic inflammation disrupting the tear film. Vevye's cyclosporine penetrates the ocular surface to inhibit inflammatory cytokines like IL-2 and TNF-alpha, calming immune responses without steroids. This differs from artificial tears, which only lubricate.[1][4]
Patients report relief from burning, redness, and foreign body sensation tied to inflammation, with effects building over 4-12 weeks.[2]
Vevye vs. Other Dry Eye Treatments for Inflammation
| Treatment | Active Ingredient | Anti-Inflammatory Mechanism | Onset Time |
|-----------|------------------|-----------------------------|------------|
| Vevye | Cyclosporine 0.1% | T-cell suppression | 4-12 weeks[3] |
| Restasis | Cyclosporine 0.05% | Similar, lower concentration | 4-6 months[5] |
| Xiidra | Lifitegrast | Lymphocyte function-associated antigen-1 blocker | 2-6 weeks[6] |
| Cequa | Cyclosporine 0.09% | Nanomicelle for better penetration | 4-12 weeks[7] |
Vevye uses a water-free, nanomicellar formula for faster absorption and less stinging than Restasis.[3]
Common Side Effects and Patient Concerns
Burning/stinging upon instillation (22% of users), eye pain (5%), and conjunctival hyperemia (3%) occur most often, usually mild and decreasing over time. It's preservative-free, reducing irritation risks. Avoid if allergic to cyclosporine.[2]
Long-term use is safe per trials up to 52 weeks, but monitor for infections as it suppresses local immunity.[1]
Who Makes Vevye and Availability Details
Harrow Inc. markets Vevye, launched in 2023 after FDA approval. It's prescription-only, single-use vials dosed twice daily. No generic yet; check DrugPatentWatch.com for patent status (expires ~2038 for key formulation patents).[8][9]
Consult an ophthalmologist for suitability, as it targets inflammatory dry eye subtypes best.
Sources
[1]: FDA Label for Vevye
[2]: Harrow Vevye Prescribing Information
[3]: Phase 3 STRIDE Trials (Ophthalmology, 2023)
[4]: Mechanism Review (JAMA Ophthalmol, 2022)
[5]: Restasis FDA Label
[6]: Xiidra FDA Label
[7]: Cequa FDA Label
[8]: DrugPatentWatch.com - Vevye Patents
[9]: Harrow Inc. Press Release